At the news
? NEUTRALIMPACT 3/10 6-K filed May 5, 2026 at 09:02 ET
Alpha Tau announced that an abstract on its Alpha DaRT combination therapy with pembrolizumab for elderly head and neck cancer patients was accepted for a podium presentation at the AHNS International Conference in July 2026. The filing is a routine clinical milestone update with no new financial data or regulatory approval, and the stock has historically not reacted positively to similar announcements.
- Abstract on Alpha DaRT + pembrolizumab in elderly HNSCC patients accepted for podium presentation at AHNS 12th International Conference (July 18-22, 2026, Boston).
- Presentation scheduled for July 21, 2026, during Proffered Papers session on Radiation and Adjuvant Therapies.
- Study conducted at Hadassah Medical Center, Jerusalem; complete top-line data to be presented.
- No financial figures, revenue, EPS, or guidance changes reported in the filing.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access